Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection.
about
Toward unraveling the complexity of simple epithelial keratins in human diseaseCytokeratins in gastroenterology. Systematic reviewPlasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysisStructural basis for executioner caspase recognition of P5 position in substratesHepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease.Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection.Intermediate filament cytoskeleton of the liver in health and diseaseKeratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies.Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma.Mechanisms of cell death in acute liver failure.Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection.Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.HCV infection clearance with functional or non-functional caspase-12.Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation.
P2860
Q24657673-BB92629D-8031-4739-A4C0-AB4479E5E52BQ26777674-A52D9B77-B3E7-43A6-9C1D-157E6C76D1A2Q27647196-267EABBA-86C2-4349-817C-906448C8C8DFQ27652050-A44D64FD-E15D-42A4-B9B8-F8635DA1CA03Q33597579-FB8606EE-BCED-4708-AFD4-57A1A09F66CCQ34698815-7B24DBE4-4F9F-4A8B-8CF8-F3D7B04A4FB8Q35139010-1B3E5917-6314-48AF-AA45-32633430CEACQ36661678-70E54FEA-B0DB-499F-B2CE-27552A5874A7Q36985178-05D13154-8008-4C8E-AF06-2D866D070FA5Q37324402-4282A874-CCA0-4FF0-BB04-6D40BD98E1C3Q38000987-FDBB69BF-326D-4A62-9621-6E7A9A648401Q38725581-B705B897-E289-4F0D-A6FF-C0E62A70DAABQ39311520-70F6C6AD-D963-48BF-899A-1E36BD17B505Q40936303-F1416D6F-41A8-424B-83FA-ECE39DC90E5AQ42249715-863BF413-BD8A-4ED8-B5D0-7F0672191A2AQ43710040-A15426D2-6D1A-4B74-9833-B2F3577FE40DQ51598731-97713968-8D31-4BE7-8186-B0DB8D798904
P2860
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Caspase activation is required ...... c hepatitis C virus infection.
@en
Caspase activation is required ...... c hepatitis C virus infection.
@nl
type
label
Caspase activation is required ...... c hepatitis C virus infection.
@en
Caspase activation is required ...... c hepatitis C virus infection.
@nl
prefLabel
Caspase activation is required ...... c hepatitis C virus infection.
@en
Caspase activation is required ...... c hepatitis C virus infection.
@nl
P2093
P356
P1433
P1476
Caspase activation is required ...... c hepatitis C virus infection.
@en
P2093
Frank Lehner
Heike Bantel
Heiner Wedemeyer
Klaus Schulze-Osthoff
Markus Cornberg
Michael P Manns
Xandra Volkmann
P304
P356
10.1002/HEP.21186
P407
P577
2006-06-01T00:00:00Z